Loading…
← CockpitCompetitor Analysis › VKTX Viking Therapeutics, Inc.Open in the cockpit ↗

Viking Therapeutics, Inc.VKTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing GLP-1/GIP obesity drugs and a thyroid-receptor agonist for fatty liver disease.

Momentum weak 34
Mkt cap
$3.34B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$112M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.7%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · USD$26.17
1D-2.6%
1W-8.0%
1M-2.0%
3M-21.6%
6M-8.8%
YTD-25.6%
1Y-32.9%
ATR %6.9%
Beta1.33
52w lowhigh38.8% off high

What Viking Therapeutics does

Clinical-stage biotech developing GLP-1/GIP obesity drugs and a thyroid-receptor agonist for fatty liver disease.

Has no product on sale and no revenue, so trial costs are paid from cash raised by selling shares. Its main drug candidate comes as a weekly injection and a daily tablet version, and a partnership or licence with a larger drug company would be the way to share the cost of late-stage trials and a launch.

Products and services

  • VK2735 (obesity, GLP-1/GIP)
  • VK2809 (NASH/dyslipidemia)
  • Oral VK2735 formulation

Where it sits in the supply chain

  • Biopharma R&D
  • Metabolic disease drug candidates
  • Obesity/NASH clinical trials

What could go right

  • Positive late-stage obesity data
  • Partnership/licensing with big pharma

What could go wrong

  • Crowded, well-funded obesity competition
  • Trial/regulatory setback risk

Moat: none (IP / patents). No approved products yet; must prove differentiation versus Novo Nordisk and Eli Lilly incumbents.

Headquarters: San Diego, California, US · Founded: 2012 · Employees: 53

Named competitors

Viking Therapeutics at a glance

Size Viking Therapeutics (VKTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.34B, the 1469th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.17 on 18 Nov 2026.

Performance Over six months the shares fell 8.8%, against -0.2% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 20 in its peer set.

Credit Viking Therapeutics has 1 bond outstanding ($259M).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 102VKTX 92
Six months, rebased to 100: Viking Therapeutics against the median of its 20 peers (local-currency closes).

Viking Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$494,000-$431,000-$346,000-$292,000-$291,000
EBITDA-$648M-$393M-$151M-$101M-$70.1M
Net income-$627M-$360M-$110M-$85.9M-$68.9M
Free cash flow-$463M-$279M-$87.8M-$73.4M-$48.4M
Capital expenditure$0$0$0$0$0
Total debt$255M$137,000$1.12M$1.26M$1.56M

Quarterly statements and history in the cockpit →

Viking Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%000739PPLPHARMA2096VRDN600511AMLX002262688180ARQTACUTAASWOCKPHARMA688266LEGN3320ACAD2696VKTX6-month return →1-month return →
Up and to the right = strong over both horizons. Viking Therapeutics is the large dot.

Viking Therapeutics competitors and peer comparison

Head to head with its named competitors (VKTX vs NOVO-B.CO vs LLY vs AMGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Viking Therapeutics VKTX$3.34B-9%n/an/an/an/a
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Structure Therapeutics, Inc. Sponsored ADR GPCR$1.24B-53%n/an/an/an/a

How Viking Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Viking Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureVKTXPeer medianRank in peer set
1-month return-2.0%-4.0%10th highest of 21
6-month return-8.8%-0.2%7th lowest of 20
Distance from 52-week high-38.8%-24.1%6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%2.5×4.7%+4.5%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%3.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
China National Medicines 600511.SSChina$3.26B+3%+3%4%0.3×-10.0%+5.4%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%8.1×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%2.2×-7.5%-9.6%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%11.0×17.7%+98.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%1.8×n/an/a
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%1.8×9.2%+19.4%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%3.3×14.1%+61.4%

Viking Therapeutics bonds and credit

Viking Therapeutics has 1 bond outstanding with $259M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Viking Therapeutics's main competitors?
Named competitors: Novo Nordisk (NOVO-B.CO), Eli Lilly (LLY), Amgen (AMGN), Structure Therapeutics (GPCR). The cockpit's measured peer set (industry) also includes Apeloa Pharmaceutical (000739.SZ), Piramal Pharma (PPLPHARMA.NS), Simcere Pharmaceutical (2096.HK), Viridian Therapeutics (VRDN), China National Medicines (600511.SS), Amylyx Pharmaceuticals (AMLX).
How has Viking Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -8.8% against -0.2% for the median peer; over one year -32.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.